Format

Send to

Choose Destination
Am J Hematol. 2019 Feb;94(2):257-265. doi: 10.1002/ajh.25338. Epub 2018 Nov 26.

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts.

Author information

1
The University of Texas MD Anderson Cancer Center, Houston, Texas.
2
NeoGenomics Laboratories, Inc., Aliso Viejo, California.
3
University Hospitals, Cleveland, Ohio.
4
Children's Hospital Colorado and University of Colorado Cancer Center, Aurora, Colorado.
5
University of California San Francisco, San Francisco, California.
6
Memorial Sloan Kettering Cancer Center, New York, New York.
7
Moffitt Cancer Center, Tampa, Florida.
8
Fred Hutchinson Cancer Research Center, Seattle, Western Australia.

Abstract

Measurable residual disease (MRD) that persists after initial therapy is a powerful predictor of relapse and survival in acute lymphoblastic leukemia (ALL). However, the optimal use of this information to influence therapeutic decisions is controversial. Herein, we comprehensively review the role of MRD assessment in adults with ALL, including methods to quantify residual leukemia cells during remission, prognostic impact of MRD across ALL subtypes, and available therapeutic approaches to eradicate MRD. This review presents consensus statements and provides an evidence-based framework for practicing hematologists and oncologists to use MRD information to make rational treatment decisions in adult patients with ALL.

PMID:
30394566
PMCID:
PMC6572728
[Available on 2020-02-01]
DOI:
10.1002/ajh.25338
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center